Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Hillhouse Capital Group
AddedMar 19, 2024
UpdatedJul 16, 2026
Hillhouse Capital Group

Hillhouse Capital Group

Operating

Global investment firm partnering with entrepreneurs for sustainable value creation in various sectors since 2005.

Location
Singapore, Singapore, SG
Founded
2005
Firm
Compare
Portfolio
Employees
News
Website

Investments

Capcon
Capcon
Public

Total Raised

$50M

Rounds

2

Series B$50MJanuary 2023
Zilliz
Zilliz

Total Raised

$113M

Rounds

4

Series B$60MAugust 2022
Series B$43MNovember 2020
CATL
CATL
Public

Total Raised

$156.1B

Rounds

7

Post Ipo Equity$45BJune 2022
Post Ipo Equity$19.7BJuly 2020
Zmo.Ai
Zmo.Ai

Total Raised

$8M

Rounds

1

Series A$8MMay 2022
CertiK
CertiK

Total Raised

$300.2M

Rounds

8

Series B$80MDecember 2021
Series B$24MAugust 2021
Alluxio
Alluxio

Total Raised

$73M

Rounds

4

Series C$50MNovember 2021
Nobell Foods
Nobell Foods
Series B

Total Raised

$75.1M

Rounds

3

Series B$75MJuly 2021
Nature's Fynd
Nature's Fynd

Total Raised

$509.6M

Rounds

6

Series C$350MJune 2021
Exegenesis Bio
Exegenesis Bio

Total Raised

$10M

Rounds

2

Series BFebruary 2021
Delivery Hero
Delivery Hero
Public

Total Raised

$8.7B

Rounds

22

Post Ipo Secondary$1.2BJanuary 2021
EMQ Technologies
EMQ Technologies

Total Raised

$140M

Rounds

3

Series B$140MDecember 2020
Horizon Robotics
Horizon Robotics
Corporate Round

Total Raised

$2.2B

Rounds

12

Series C$150MDecember 2020
Full Truck Alliance
Full Truck Alliance
Public

Total Raised

$3.6B

Rounds

6

Private Equity$1.7BNovember 2020
Cytek Biosciences
Cytek Biosciences
Public

Total Raised

$144.3M

Rounds

6

Series D$120MNovember 2020
Zhaoke Ophthalmology Pharmaceutical
Zhaoke Ophthalmology Pharmaceutical
Public

Total Raised

$145M

Rounds

1

Series B$145MOctober 2020
Xpeng
Xpeng
Public

Total Raised

$30.7B

Rounds

12

Series C$500MJuly 2020
BeOne Medicines
BeOne Medicines
Public

Total Raised

$6.8B

Rounds

8

Post Ipo Equity$2.1BJuly 2020
Coalition
Coalition

Total Raised

$770M

Rounds

7

Series C$90MMay 2020
Series B$25MMay 2019
MicroPort CardioFlow
MicroPort CardioFlow
Public

Total Raised

$130M

Rounds

1

Private Equity$130MApril 2020
Aier Eye Hospital Group
Aier Eye Hospital Group
Public

Total Raised

$1.9B

Rounds

4

Post Ipo Equity$1.9BSeptember 2019
Trumid
Trumid

Total Raised

$658.3M

Rounds

8

Series D$60MMay 2019